Trial Profile
A Phase 2 Study of Neratinib With or Without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Mar 2023
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Fulvestrant
- Indications Advanced breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 17 Mar 2023 Status changed from active, no longer recruiting to discontinued.
- 02 Mar 2022 Planned primary completion date changed from 31 Jan 2022 to 31 Oct 2022.
- 01 Oct 2021 Planned primary completion date changed from 31 Aug 2021 to 31 Jan 2022.